Leveraging Ginkgo's plant-cell assay and engineering capabilities to aid Light Bio in optimizing the performance of its light-emitting plants The scientists at Light Bio have discovered a new type of ...

BOSTON, Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...

Ginkgo Bioworks' stock price has been volatile due to mixed Q2 earnings, partnership announcements, and concerns about the macro environment. Antheia recently achieved a successful full-scale ...

BOSTON and BERLIN, Oct. 2, 2023 /PRNewswire/ -- Nosh.bio, a German startup developing highly functional ingredients from fungal biomass for animal-free food products, and Ginkgo Bioworks (DNA), which ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $15.12, demonstrating a -4.49% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a ...

BOSTON — Ambrosia Bio and Ginkgo Bioworks are partnering to use Ginkgo’s Enzyme Services to formulate an expression strain for the production of Ambrosia Bio’s proprietary enzymes used for the ...

The cell and gene therapy field is, some say, at a tipping point—poised to take off. The FDA has noted that, by next year, they aim to approve 10–20 new cell and gene therapies per year. To do that, ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and ...